Empowering health – The dawn of a transformative era in medical device manufacturing in India

In the ever-evolving landscape of healthcare, a remarkable revolution is unfolding as India embraces the principles of Make in India and Develop in India for medical devices. This pivotal shift is poised to position India as a prominent player in the global medical devices market, projected to reach an astonishing USD 850 billion by 2030.

With an unwavering commitment to a healthier and happier world, Transasia-Erba stands at the forefront of this transformation. The core of our vision hinges on reducing disease prevalence by prioritizing early and precise diagnostics – a fundamental aspect of a healthier society.

However, in a country of 1.3 billion, where basic healthcare infrastructure remains uneven, the task of providing regular diagnostic services poses a monumental challenge. This underscores the critical need for a robust healthcare ecosystem, encompassing both manufacturing and research infrastructure. The imperative lies in minimizing dependency on imports and fostering a self-reliant ecosystem.

Transasia-Erba, as an Indian MNC manufacturing in India, for India and the world, plays a vital role in this endeavor. Our focus is threefold – fortifying our product portfolio through cutting-edge research and development, scaling our manufacturing capabilities to global standards, and reaching the remotest of towns and villages across India, ensuring good health for all. Today, our equipment conducts a staggering 150 crore blood tests annually, a testament to equal opportunities for success in India.

Technological advancements take center stage as we address the spectrum of infectious diseases and non-communicable diseases prevalent in India’s diverse landscape. Collaborations between our Indian and global R&D teams are driving breakthroughs, particularly in areas like molecular testing for diseases, such as HIV, TB, and cancer. Further, we are set to diversify our product offerings in critical care, diabetes, clinical chemistry, coagulation, and ESR.

Innovations in the pipeline include an integrated system, a next-generation modular solution for hematology, immunoassay, and clinical chemistry suitable for mid-sized labs. This underscores our dedication to innovation that aligns with India’s healthcare needs.

Furthermore, strengthening our R&D and manufacturing prowess remains pivotal, and we laud the government’s creation of dedicated medical device parks to incentivize indigenous production. Our upcoming factory of the future is poised to offer state-of-the-art diagnostic instruments and test kits, bolstering the nation’s healthcare capabilities.

I believe to craft reliable, affordable, and innovative medical diagnostic solutions one needs to constantly stay updated with relevant subject matter knowledge, coupled with the technical know-how. In this direction, our contribution extends beyond manufacturing; Transasia-Erba is pioneering India’s first Med-Tech University, Transasia Global University, focused on advanced, research-based education in medical technology.

Looking ahead, our journey encompasses a slew of advancements. From innovative diagnostic systems in various domains to groundbreaking offerings in CLIA, molecular, high-end hematology, artificial intelligence, and LIS, we are poised to launch an inventive and budget-friendly total lab automation solution. This strategic roadmap positions Transasia-Erba among the global elite, with total solutions in laboratory diagnostics.

As India takes confident strides toward a self-reliant and innovative healthcare ecosystem, Transasia-Erba stands steadfast in its commitment to empower health, foster innovation, and shape a healthier and happier future for all.